• Mashup Score: 0

    Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy is transforming the care of patients with relapsed/refractory multiple myeloma (MM). Unfortunately, despite being a disease of older adults these patients remain under-represented in most pivotal clinical trials. We performed a systematic review and proportion meta-analysis of prospective clinical trials and observational studies of anti-BCMA CAR-T therapy in patients with MM with the aim to determine the efficacy and safety of this therapy in older adults (≥65 years).

    Tweet Tweets with this article
    • Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis https://t.co/fO900h0XcF @WilliamDale_MD @rochgerionc @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #CellularTherapy #CARTTherapy https://t.co/pineBpKNy2

  • Mashup Score: 1

    During the European Hematology Association (EHA) 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint session entitled ‘The ins and o…

    Tweet Tweets with this article
    • Doris Hansen, Moffitt Cancer Center, Tampa, US, shares a real-world patient case. Watch to learn about the safety and efficacy of CAR T-cell therapy in the real-world setting! 👉 https://t.co/JdYCMgftXA #mmsm #myeloma #CARTtherapy #EHA2023 https://t.co/vfrmTVNTIC

  • Mashup Score: 1

    During the European Hematology Association (EHA) 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint session entitled ‘The Ins and o…

    Tweet Tweets with this article
    • At our #EHA2023 symposium, Shaji Kumar @myelomaMD, discussed: Biomarkers and patient eligibility for CAR T-cell therapies in #multiplemyeloma. Watch the presentation, including questions from Ulrich Jäger and the audience. 👉 https://t.co/MddYweilI3 #mmsm #CARTtherapy #myeloma https://t.co/DsMw7aoCfw

  • Mashup Score: 2

    During the EHA 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite session on the ins and outs of CAR T-cells in the real world. Here we share a presentation by Shaji Kumar, Mayo Clinic, Rochester, US, on biomarkers and eligibility for CAR T-cell therapies in multiple myeloma.

    Tweet Tweets with this article
    • At our #EHA2023 session, Shaji Kumar @myelomaMD, discussed: Biomarkers and patient eligibility for CAR T-cell therapies in #multiplemyeloma. Watch the presentation, including questions from Ulrich Jäger and the audience. 👉 https://t.co/fsv9L2jhZw #mmsm #CARTtherapy #myeloma https://t.co/lexesWhAAN https://t.co/Fsm9mCeWjY

  • Mashup Score: 2

    At the EHA 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint symposium on the ins and outs of CAR T-cells in the real world. Here, Doris Hansen shares a patient case.

    Tweet Tweets with this article
    • Doris Hansen, Moffitt Cancer Center, Tampa, US, shares a real-world patient case. Watch to learn about the safety and efficacy of CAR T-cell therapy in the real-world setting! 👉 https://t.co/Wn4T7A8lxm #mmsm #myeloma #CARTtherapy #EHA2023 https://t.co/jIun53efCk

  • Mashup Score: 0

    During the EHA 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium on the ins and outs of CAR T-cells in the real world. Here we share a presentation by Shaji Kumar, Mayo Clinic, Rochester, US, on biomarkers and eligibility for CAR T-cell therapies in multiple myeloma.

    Tweet Tweets with this article
    • At our #EHA2023 symposium, Shaji Kumar @myelomaMD, discussed: Biomarkers and patient eligibility for CAR T-cell therapies in #multiplemyeloma. Watch the presentation, including questions from Ulrich Jäger and the audience. 👉 https://t.co/fsv9L2jhZw #mmsm #CARTtherapy #myeloma https://t.co/fG52apSITT

  • Mashup Score: 1

    Strategically boosting CAR T cells aimed at an improved target could help improve immunotherapy efficacy in prostate cancer, according to preclinical work from Fred Hutchinson Cancer Center scientists, published in Nature Communications in April.

    Tweet Tweets with this article
    • Preclinical work led by @vipulbhatia24, @jklee_lab identifies improved target and recruits more immune cells to make #CARTtherapy work better for advanced #prostatecancer. https://t.co/u1tQ3ObEIh

  • Mashup Score: 2

    Strategically boosting CAR T cells aimed at an improved target could help improve immunotherapy efficacy in prostate cancer, according to preclinical work from Fred Hutchinson Cancer Center scientists, published in Nature Communications in April.

    Tweet Tweets with this article
    • Preclinical work led by @vipulbhatia24, @jklee_lab identifies improved target and recruits more immune cells to make #CARTtherapy work better for advanced #prostatecancer. https://t.co/u1tQ3ObEIh

  • Mashup Score: 4

    This Perspective reviews recent developments in the design and use of chimeric antigen receptors in treatments for cancers and other diseases.

    Tweet Tweets with this article
    • SCI member @MackallLab summarizes the challenges facing #CARTtherapy and previews the next generation of #CellTherapy, spanning novel receptor designs, manufacturing platforms, immune cell types and promising indications beyond cancer. https://t.co/TlfY5BB79E https://t.co/bOgjPKhUKp